경구 거담제 시장 : 약물 유형, 제형, 의약품, 유통 채널별 - 세계 예측

Oral expectorant market size is set to record 3.4% CAGR from 2024 to 2032, driven by the increasing prevalence of respiratory diseases, such as asthma, chronic bronchitis, and COPD (Chronic Obstructive Pulmonary Disease) worldwide. As per WHO, currently 392 million people suffer from COPD worldwide. These conditions can cause symptoms like cough and mucus production, further increasing the need for oral contraceptives as a common treatment option. Moreover, the risk of respiratory diseases is increasing due to air pollution, smoking and lifestyle changes, favoring the product adoption.

With the growing aging population and increasing respiratory diseases, the need for oral ventilators is intensifying. Rapid advancements in healthcare infrastructure and higher availability of over the counter (OTC) drugs in pharmacies and online platforms will also provide opportunities to access oral prospects, supporting the market growth.

The oral expectorant industry is segmented into drug type, dosage form, medication, distribution channel, and region.

Based on drug type, the market size from the mucolytics segment will record 3.1% growth rate between 2024 and 2032, due to its efficiency in treating respiratory conditions characterized by thick and tenacious mucus, such as chronic bronchitis and cystic fibrosis. Mucolytics help thin and loosen mucous secretions, making it easier for people to clear their airways when they cough. This method of operation also reduces symptoms, such as chest congestion and dyspnea for increasing the patients need for mucolytics while providing recommendations for healthcare professionals.

With regards to distribution channel, the oral expectorant market from the online pharmacies segment is anticipated to witness 2.9% CAGR from 2024-2032, favored by convenient access to a wide range of expectorant medications for consumers. With the increase in infections and respiratory diseases, such as cough and runny nose, oral medicine clinics help in providing patients with easy access to over-the-counter expectorant products. Furthermore, increased availability of pharmacists for advice and guidance on appropriate expectorant choices will increase consumer confidence and product use.

Asia Pacific oral expectorant industry size will record sustained growth at 4% CAGR through 2032, attributed to urbanization, industrialization, and environmental pollution. Large population, increasing awareness about respiratory health and strong access to healthcare services will drive the product adoption. The wide variety of oral expectorant formulations available to meet regional needs and regulatory systems is also contributing to the market growth in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory disease
    • 3.2.1.2 Growing demand for OTC medications
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Increasing awareness among people about respiratory conditions
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Strict government and regulatory guidelines
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Secretion enhancer
  • 5.2.1 Potassium citrate
  • 5.2.2 Potassium iodide
  • 5.2.3 Sodium citrate
  • 5.2.4 Guaiphenesin
  • 5.2.5 Ammonium chloride
  • 5.2.6 Other secretion enhancer
• 5.3 Mucolytics
  • 5.3.1 Bromhexine
  • 5.3.2 Ambroxol
  • 5.3.3 Acetyl cysteine
  • 5.3.4 Carbocisteineurine

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral solids
  • 6.2.1 Powder & granules
  • 6.2.2 Tablet
  • 6.2.3 Capsule
• 6.3 Oral liquids
  • 6.3.1 Syrup
  • 6.3.2 Solution
  • 6.3.3 Suspension
• 6.4 Inhalants

Chapter 7 Market Estimates and Forecast, By Medication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription drugs
• 7.3 Over-the-counter drugs

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail store & drug store
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AstraZeneca
• 10.3 Cipla Inc.
• 10.4 Genexa Inc.
• 10.5 GlaxoSmithKline (GSK) plc
• 10.6 Merck KGaA
• 10.7 Perrigo Company plc
• 10.8 Reckitt Benckiser Group PLC
• 10.9 Sanofi
• 10.10 Sun Pharmaceutical Industries Ltd.
• 10.11 The Himalaya Drug Company